Detalles de la búsqueda
1.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet
; 397(10275): 671-681, 2021 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33545094
2.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Lancet
; 396(10255): 887-897, 2020 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32896291
3.
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.
Front Immunol
; 14: 1129245, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37063833
4.
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Front Immunol
; 14: 1228461, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37600800
5.
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals.
Vaccines (Basel)
; 10(5)2022 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35632574
6.
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
Emerg Microbes Infect
; 11(1): 2229-2247, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031930
7.
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus.
Front Immunol
; 13: 1023164, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36466896
8.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.
Lancet Reg Health Eur
; 11: 100241, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34746910
9.
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants.
Vaccines (Basel)
; 9(7)2021 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34358195
Resultados
1 -
9
de 9
1
Próxima >
>>